AGILE: Phase 3 Study of Ivosidenib + Azacitidine vs Placebo + Azacitidine in Patients with AML and an IDH1 Mutation
Event Type:
Webinars
Date:
Tuesday, May 17, 2022, 2-3pm ET
Member:
Payers/HCDMs Only (Free)
Non-Member:
Payers/HCDMs Only (Free)
